Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
暂无分享,去创建一个
Seth Love | Ghasem Yadegarfar | Anthony Bayer | Roy W Jones | James W Neal | C. Holmes | S. Love | A. Bayer | R. Bullock | D. Boche | D. Wilkinson | G. Yadegarfar | Vivienne Hopkins | J. Neal | E. Zotova | J. Nicoll | Clive Holmes | Vivienne Hopkins | Roger Bullock | David Wilkinson | Delphine Boche | Elina Zotova | James AR Nicoll | Roy W Jones | Roy W Jones
[1] John Q. Trojanowski,et al. Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.
[2] J. Hardy,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.
[3] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[4] K. Henke,et al. Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.
[5] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[6] D. Wilcock,et al. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. , 2007, Neuroscience.
[7] K. Henke,et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.
[8] J. Trojanowski,et al. Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.
[9] J. Joseph,et al. Predicting the failure of amyloid-beta vaccine. , 2002, Lancet.
[10] A. Delacourte,et al. Absence of β-amyloid deposits after immunization in Alzheimer disease with lewy body dementia , 2007 .
[11] Brian J. Bacskai,et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.
[12] J. Joseph,et al. Predicting the failure of amyloid-β vaccine , 2002, The Lancet.
[13] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[14] D. Wilcock,et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.
[15] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[16] F. Schmitt,et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.
[17] M. Staufenbiel,et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. , 2002, Science.
[18] R. Black,et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. , 2005, Annals of neurology.
[19] I. Ferrer,et al. Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis , 2006 .
[20] Ian G. McKeith,et al. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.
[21] L. Jenkins,et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.
[22] H. Weiner,et al. Immunology and immunotherapy of Alzheimer's disease , 2006, Nature Reviews Immunology.
[23] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[24] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[25] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[26] S. Gauthier,et al. Functional Disability in Alzheimer's Disease , 1997, International Psychogeriatrics.
[27] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[28] R. Black,et al. Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies , 2005 .
[29] J. Hardy,et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.
[30] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[31] J. Hardy,et al. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? , 2006, Current Alzheimer research.
[32] A. Delacourte,et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. , 2007, Archives of neurology.
[33] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[34] R. Sperling,et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. , 2003, The Journal of clinical investigation.
[35] M. Mattson,et al. Good and Bad Amyloid Antibodies , 2003, Science.